Insilico Reports Annual Results with Over 10 New Partnerships and $393 Million Cash Reserves

Stock News03-29

Insilico (03696) announced its 2025 financial results on March 29, 2026. The company listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, achieving the largest fundraising scale among biopharmaceutical IPOs on the Hong Kong stock market for that year. By the end of 2025, cash and bank balances reached $393 million, with annual revenue totaling $56.24 million.

On the platform front, the company completed upgrades across the three core modules of its Pharma.AI platform—Biology, Chemistry, and Science—and launched TargetBench 1.0, a benchmark for target discovery; Nach01, a multimodal chemical foundation model; and MMAI Gym, a training framework for large models.

In R&D, the company nominated six preclinical candidate drugs throughout the year and advanced eight projects into clinical stages. In terms of R&D collaborations, over 10 new partnerships were established, with a total value of $1.3 billion. Multiple projects also achieved milestones and generated revenue.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1183769642?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-29 20:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1183769642","market":"sh","top_or_hot":-1,"title":"Insilico Reports Annual Results with Over 10 New Partnerships and $393 Million Cash Reserves","media":"Stock News","content":"<p>Insilico (03696) announced its 2025 financial results on March 29, 2026. The company listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, achieving the largest fundraising scale among biopharmaceutical IPOs on the Hong Kong stock market for that year. By the end of 2025, cash and bank balances reached $393 million, with annual revenue totaling $56.24 million.</p>\n<p>On the platform front, the company completed upgrades across the three core modules of its Pharma.AI platform—Biology, Chemistry, and Science—and launched TargetBench 1.0, a benchmark for target discovery; Nach01, a multimodal chemical foundation model; and MMAI Gym, a training framework for large models.</p>\n<p>In R&D, the company nominated six preclinical candidate drugs throughout the year and advanced eight projects into clinical stages. In terms of R&D collaborations, over 10 new partnerships were established, with a total value of $1.3 billion. Multiple projects also achieved milestones and generated revenue.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Insilico Reports Annual Results with Over 10 New Partnerships and $393 Million Cash Reserves</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInsilico Reports Annual Results with Over 10 New Partnerships and $393 Million Cash Reserves\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-29 20:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Insilico (03696) announced its 2025 financial results on March 29, 2026. The company listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, achieving the largest fundraising scale among biopharmaceutical IPOs on the Hong Kong stock market for that year. By the end of 2025, cash and bank balances reached $393 million, with annual revenue totaling $56.24 million.</p>\n<p>On the platform front, the company completed upgrades across the three core modules of its Pharma.AI platform—Biology, Chemistry, and Science—and launched TargetBench 1.0, a benchmark for target discovery; Nach01, a multimodal chemical foundation model; and MMAI Gym, a training framework for large models.</p>\n<p>In R&D, the company nominated six preclinical candidate drugs throughout the year and advanced eight projects into clinical stages. In terms of R&D collaborations, over 10 new partnerships were established, with a total value of $1.3 billion. Multiple projects also achieved milestones and generated revenue.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1141","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"","article_id":"1183769642","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1183769642","pubTimestamp":1774787296,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Insilico (03696) announced its 2025 financial results on March 29, 2026. The company listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, achieving the largest fundraising...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1141":"生命科学工具和服务","03696":"英矽智能"},"translate_title":"Insilico公布年度业绩，拥有10多个新合作伙伴和3.93亿美元现金储备","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03696":1},"content_text":"Insilico (03696) announced its 2025 financial results on March 29, 2026. The company listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, achieving the largest fundraising scale among biopharmaceutical IPOs on the Hong Kong stock market for that year. By the end of 2025, cash and bank balances reached $393 million, with annual revenue totaling $56.24 million.\nOn the platform front, the company completed upgrades across the three core modules of its Pharma.AI platform—Biology, Chemistry, and Science—and launched TargetBench 1.0, a benchmark for target discovery; Nach01, a multimodal chemical foundation model; and MMAI Gym, a training framework for large models.\nIn R&D, the company nominated six preclinical candidate drugs throughout the year and advanced eight projects into clinical stages. In terms of R&D collaborations, over 10 new partnerships were established, with a total value of $1.3 billion. Multiple projects also achieved milestones and generated revenue.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1183769642","isCrawlerRequest":true}